REGENXBIO Inc. (RGNX)
REGENXBIO Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
REGENXBIO Inc. (RGNX) is a Biotechnology company based in US with a market capitalization of $534.6M. Revenue grew 104.5% year-over-year and free cash flow was negative at -$126.4M. This page tracks RGNX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 353 employees · IPO Sep 17, 2015
Valuation
Valuation & price
$5.72as of May 17, 2026· -64.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
5.20
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$534.6M
Market cap
104.5%
Revenue growth (YoY)
88.1%
Gross margin
-$126.4M
Free cash flow (USD)
$30.4M
Net debt
4.2%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
3
Insider sells · 90 days
Earnings
Last reported: May 14, 2026 (EPS $-1.72)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 20, 2026Filing
Common Stock Offering
- Insider sellJul 6, 2026Filing
Insider Sell $29K · 10b5-1 PlanPAKOLA STEVE · Chief Medical Officer · $29.5K
- Insider sellJul 1, 2026Filing
Insider Sell $689K · 10b5-1 PlanPAKOLA STEVE · Chief Medical Officer · $688.8K
- 8-K eventJun 29, 2026Filing
Milestone Payment Received
- 8-K eventJun 3, 2026Filing
Annual Meeting Results
- 8-K eventMay 14, 2026Filing
Earnings Release
- Quarterly reportMay 14, 2026Filing
10-Q Filed
- Insider sellMay 13, 2026Filing
Insider Sell $169K · 10b5-1 PlanPAKOLA STEVE · Chief Medical Officer · $168.7K
Questions
Frequently asked questions
What is REGENXBIO Inc.'s market cap?
REGENXBIO Inc. (RGNX) has a market capitalization of $534.6M.
What is RGNX's P/E ratio?
A meaningful P/E ratio is not available for RGNX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is RGNX's price-to-book (P/B) ratio?
RGNX trades at 5.20 times book value per share.
When did REGENXBIO Inc. last report earnings?
RGNX last reported earnings on May 14, 2026; the next date is not yet scheduled.
Are insiders buying RGNX stock?
SEC Form 4 filings show no open-market insider buys at REGENXBIO Inc. in the last 90 days (3 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.